Novel Bispecific Antibody for Synovial-Specific Target Delivery of Anti-TNF Therapy in Rheumatoid Arthritis.

Front Immunol · 2021 · PMC7933454 · PMID 33679801

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

a decreasing trendp < 0.05actually significant

A similar B-cell (CD20) and fibroblast (CD90) content was present in all tissues tested ( Figure 4B e,f), while a decreasing trend for T cells (CD3) could be detected in the adalimumab scFv-Fc ( p < 0.05 and p = 0.05) and A7/adalimumab ( p = 0.1 and p = 0.05) treatment groups compared to control and E2/adalimumab ( Figure 4B c).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.